Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;11(8):2166-2175.
doi: 10.1002/acn3.52137. Epub 2024 Jul 25.

Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody-associated disease

Ruth Schneider  1   2 , Ann-Kathrin Kogel  1 , Theodoros Ladopoulos  1   2 , Nadine Siems  1 , Britta Krieger  2 , Barbara Bellenberg  2 , Ralf Gold  1 , Ilya Ayzenberg  1 , Carsten Lukas  2
Affiliations

Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody-associated disease

Ruth Schneider et al. Ann Clin Transl Neurol. 2024 Aug.

Abstract

Objectives: Global brain volume changes in patients with myelin oligodendrocyte glycoprotein antibody-associated disease compared with healthy controls (HC) could be revealed by magnetic resonance imaging, but specific atrophy patterns of cortical structures and relation to cognitive impairment are not yet comprehensively known. Thus, we aimed to investigate cortical thickness differences in patients with myelin oligodendrocyte glycoprotein antibody-associated disease compared with HC.

Methods: 3-Tesla brain magnetic resonance imaging was performed in 23 patients with myelin oligodendrocyte glycoprotein antibody-associated disease and 49 HC for voxel-wise group comparisons and neuropsychological testing in patients. Surface-based morphometry with region of interest-based surface analysis and region of interest-based extraction of cortical thickness was performed in patients compared with HC and in patient subgroups with and without cognitive impairment.

Results: Comparing patients with myelin oligodendrocyte glycoprotein antibody-associated disease with HC, exploratory surface-based morphometry demonstrated cortical volume reduction in pericalcarine and lingual cortical regions. Region of interest-based surface analysis specified reduced cortical thickness in the adjacent pericalcarine and orbitofrontal regions in myelin oligodendrocyte glycoprotein antibody-associated disease, as well as reduced temporal cortical thickness in patients with cognitive impairment (n = 10). Patients without cognitive impairment (n = 13) showed only circumscribed cortical brain volume loss compared with HC in the pericalcarine region.

Interpretation: In conclusion, cortical atrophy in myelin oligodendrocyte glycoprotein antibody-associated disease was characterized by cortical thickness reduction in the adjacent pericalcarine and orbitofrontal regions, with a tendency of temporal thickness reduction in cognitively impaired patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest with the present work. Irrespective of the present work the authors report following conflict s of interest: R.S. has received speaker's honoraria from Bayer HealthCare, Alexion Pharma, Novartis Pharma, and Roche Pharma AG, congress travel support from Merck, Biogen Idec GmbH and has received research scientific grant support from Novartis Pharma. T.L.: has received research scientific grant support from Novartis Pharma. A.K., N.S., B.K., B.B.: nothing to disclose. R.G.: has received compensation for serving as a consultant or speaker from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience; he, or the institution he works for, has received research support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience; he has also received honoraria as a Journal Editor from SAGE and Thieme Verlag. I.A.: has received travel grants from Alexion, BMS, Horizon, Roche, Biogen Idec, and Guthy‐Jackson Charitable Foundation, served on scientific advisory boards for Merck, Roche, Alexion, Horizon, and Sanofi and received research support from Diamed and Roche. C.L.: received a research grant by the German Federal Ministry for Education and Research, BMBF, German Competence Network Multiple Sclerosis (KKNMS), grant no.01GI1601I, has received consulting and 415 speaker's honoraria from Biogen Idec, Bayer Schering, Daiichi Sanykyo, Merck Serono, Novartis, 416 Sanofi, Genzyme, and TEVA.

Figures

Figure 1
Figure 1
ROI‐based surface analysis between groups with color‐coded significantly reduced cortical regions: (A) Significant reduced CT in MOGAD group compared with HC; (B) Significant reduced CT in MOG_Ci group compared with HC; (C) Significant reduced cortical thickness in MOG_Ci compared with MOG_Cp. Color‐coded p‐values in the rank between 0.049 (blue) and 0.0027 (red).
Figure 2
Figure 2
Correlations between cortical thickness of left inferior temporal and middle temporal regions with visual reproduction (WMS‐R).
See this image and copyright information in PMC

References

    1. Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody‐associated demyelinating diseases. Nat Rev Neurol. 2013;9(8):455‐461. - PubMed
    1. Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022;13:885218. - PMC - PubMed
    1. Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301‐309. - PMC - PubMed
    1. Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody‐mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617‐627. - PubMed
    1. Cortese R, Battaglini M, Prados F, et al. Clinical and MRI measures to identify non‐acute MOG‐antibody disease in adults. Brain. 2023;146(6):2489‐2501. - PubMed

LinkOut - more resources